Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page 7 t1 a. l) F# G6 O$ U
4 X* [* E9 M2 _! D( I8 ?/ Q
& G5 G6 R& `" N; ?: p0 {) OSub-category:
. h2 B- {: n6 @9 V$ [8 u; Q' `2 V, ^Molecular Targets
9 X0 W; @4 a7 Z3 @% ]5 M8 {1 o6 \/ h; `0 y* r; @% H9 Q
" {$ e; i; r4 G3 c0 U
Category:
6 T' w' @& ?# b/ M3 V. nTumor Biology 2 Y9 D6 v1 F0 D4 E
/ q& ~' F! g% j* O) ^! l& X' B
9 w/ O4 s' _) x* O1 |" `: v
Meeting:1 ^: E$ m; }! z. q& Y/ r/ E( Q0 V
2011 ASCO Annual Meeting 3 q/ A. R3 D+ M W9 ]
3 s% E0 q1 b7 `
% z0 u+ e2 j. {. P3 O2 y7 Z3 A4 eSession Type and Session Title:6 Q, r) K5 @1 f, M. u
Poster Discussion Session, Tumor Biology
+ v8 l# {! {9 A- X% D
5 A% k, Q$ l8 S# i
" L# I6 u2 [ WAbstract No:
/ n% c, k7 ^# b/ \4 D: g10517 2 c1 ]+ G o* u( U2 S
5 b U4 T E* h- l0 i4 V# _" @1 \
' T2 F5 Q4 D# W
Citation:* z1 ~+ h z* N( P) `0 d
J Clin Oncol 29: 2011 (suppl; abstr 10517)
/ _ P# U. f5 C1 G$ \0 r" a0 O c2 k, `& W, `
( k9 e3 l6 X3 J( T% C8 d+ A
Author(s):
- g8 m% G: E$ h5 d/ K4 n* lJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China # z$ r e* q' \0 V% l
! U3 s- r; n" X" [1 K; u
* {& r5 { u9 q/ G
: c, x' P# p6 `4 ]3 k
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! l1 U3 M$ M' u5 ?# |) b; j
( n& q: Z+ }% U ?, g* c
Abstract Disclosures- [/ N* {# \3 q" A
4 _/ t& a1 k, r0 | z
Abstract:" n" t& j0 S/ k( R; ?' ?
; X/ {- o8 g$ G* x3 M4 p d
, K( _" F& p) I5 I. LBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
* F4 j [9 Q! a( f, h: r, L+ b# G0 | K/ j7 O e
# N. W o$ `( k5 s4 [2 n1 k |
2 {) g" G# c7 B0 k! A! g8 A
显身卡
